Narsee Monjee Institute of Management Studies is a private university located in Mumbai, Maharashtra, India. This institute was established in 1981 by the parent body Shri Vile Parle Kelavani Mandal. It has been awarded "Five Star" rating and "A" grade by the NAAC and UGC respectively. NMIMS has also been awarded the ISO 9001:2000 Certification by ICL in 2004 and a "A***" rating by CRISIL. The institute was granted "Deemed University" status by the UGC in 2003 and can hence grant full academic degrees on its students. It has campuses in Mumbai, Shirpur, Bengaluru and Hyderabad. It offers courses/programs across diverse fields such as Management, Technology, Science, Architecture, Pharmacy, Commerce and Economics. Wikipedia.
Masurkar P.P.,Narsee Monjee Institute of Management and Higher Studies
Asian Journal of Pharmaceutical and Clinical Research | Year: 2017
India is one of the top producers of generics globally and is currently being recognized as the “pharmacy of the world” for the generic drug products. Thus, there is a need that it has best health-care systems in place to regulate and provide better quality drugs by monitoring the possible risk associated with the use of drugs. Being the generic hub, physicians, pharmacists, etc., should be erudite to provide an alternative cost-effective generic medicine, which is one of the education-related aspects of pharmacovigilance. We need a more systematic approach to surveillance of drug-related problems, which is at the heart of pharmacovigilance. The health-care system requires new processes to understand the risk-benefit ratio of drugs. The challenges in implementation of better pharmacovigilance in country due to nonavailability of trained staff in pharmacovigilance, lack of training of health-care professionals on drug safety, and adverse drug reaction reporting which comprises adverse interactions of medicines with chemicals, other medicines, and food are often neglected leading to under-reporting by health-care professionals as well as patients, lack of expertise, etc., should be overcome by Indian regulatory body via practical oriented knowledge-based system. The web market monitoring, global electronic database, education, association of stakeholders and regulation of herbal medicines standards and allied medicinal systems are vital restructurings needed to be introduced for a better pharmacovigilance system in India. © 2017 The Authors.
Veeranjaneyulu A.,Narsee Monjee Institute of Management and Higher Studies
Archives of Medical Research | Year: 2014
Background and Aims: Diabetes is a risk factor for exacerbated outcome after acute myocardial infarction (AMI) and doubles the risk of mortality after MI. Increased levels of MMP-2 and MMP-9 in diabetes cause vascular remodelling, which leads to cardiovascular complications of diabetes. We hypothesized that inhibition of MMP-2 and MMP-9 can reduce worsening of myocardial ischemia in diabetic patients. Further, we hypothesized that minocycline induced MMP-2 and MMP-9 inhibition will be potentiated by aspirin and the combination of both drugs will prevent worsening of MI in diabetic patients. In the present study, efficacy of combination of minocycline and aspirin to attenuate exacerbation of myocardial ischemia/reperfusion (I/R) injury in diabetic rats was evaluated. Methods: Diabetes was induced in male Wistar rats by streptozotocin (55 mg/kg i.p.). Three weeks after diabetes induction, rats were treated with minocycline (50 mg/kg, p.o.), aspirin (50 mg/kg, p.o.), or minocycline (50 mg/kg, p.o.) plus aspirin (50 mg/kg, p.o.) for a period of 3 weeks. At the end of week 6, I/R injury was induced by ligating the left anterior descending coronary artery for 30 min followed by 2 h reperfusion. Results: Percentage infarct volume, arrhythmias, mortality, collagen level and MMP-2 and MMP-9 level were significantly increased in vehicle-treated diabetic group when compared with normoglycemic rats. Treatment with a combination of minocycline and aspirin decreased percentage infarct volume, arrhythmias, mortality and collagen level when compared with vehicle-treated diabetic controls and showed reduced levels of MMP-2 and MMP-9. Conclusions: Results of the present study suggest that the combination of minocycline and aspirin prevent worsening of AMI in diabetic rats. © 2014 IMSS.
Das S.,Narsee Monjee Institute of Management and Higher Studies |
Suresh P.K.,Pandit Ravishankar Shukla University
Nanomedicine: Nanotechnology, Biology, and Medicine | Year: 2011
Present limitations in the management of ophthalmic fungal infections include the inability to provide long-term extraocular drug delivery without compromising intraocular structures and/or systemic drug exposure. In the present study, the potential of Eudragit RS 100 nanoparticles (NPs) as a new vehicle for the improvement of the delivery of drugs to the ocular mucosa was investigated. Amphotericin B (AmB) was chosen as a model compound because of its potential usefulness for the treatment of fungal diseases. A solvent displacement technique was used to produce AmB-loaded Eudragit NPs. These NPs had a mean size range of 150-290 nm and a zeta potential of +19-28 mV. Even after 6 months of stability study, results were unchanged, indicating the good potential for ocular application. In vitro release studies revealed that a maximum amount of drug was released within 24 hours (60%). The results obtained from microbial assay showed that the antifungal activity of drug-loaded NPs was equal to or slightly lower than that of free-AmB solution. In vivo experiments showed that, following topical instillation of nanosuspension to a rabbit's eye there was no irritation. From these results we can conclude that Eudragit RS 100 nanosuspension may represent an efficacious vehicle to deliver the drug into the eye. From the Clinical Editor: Amphotericin B encapsulated into Eudragit, a mildly cationic nanoparticle, was shown to have 6 month stability, release 60% of its drug payload in dissolution within 24 hours, and elicited no irritation when instilled into rabbit eyes. The concept is being considered for local ophthalmologic therapy of fungal disease. © 2011 Elsevier Inc.
Pandharinath R.R.,Narsee Monjee Institute of Management and Higher Studies
Journal of Ayurveda and Integrative Medicine | Year: 2011
Dr. Ashok D.B. Vaidya, the stalwart in the fields of Experimental Pharmacology, Clinical Pharmacology, and Reverse Pharmacology turns 75 on Nov, 27, 2011. A former Clinical Research Head of CIBA Geigy Research Centre, his name has been synonymous with the concept of the Golden Triangle for resurgence of Ayurveda and its reinterpretation in modern scientific terms. At a time when most fields are populated by intellectual dwarfs and unethical operators, he stands like a giant-a scientist, a philosopher, and an ardent fighter for ethical values. In this free-wheeling interview with Ravindra R.Pandharinath, he discusses the milestones in his life, his inspirations, and dreams for the confluence of modern science, modern medicine, and Ayurveda as the new health care model for the 21st century.
Rane R.A.,Narsee Monjee Institute of Management and Higher Studies |
Gutte S.D.,Narsee Monjee Institute of Management and Higher Studies |
Sahu N.U.,Narsee Monjee Institute of Management and Higher Studies
Bioorganic and Medicinal Chemistry Letters | Year: 2012
In an attempt to identify new potential lead as antimicrobial agent, twenty hybrids of marine bromopyrrole alkaloids with 1,3,4-oxadiazole were designed based on molecular hybridization technique and synthesized. Synthesized molecules were evaluated for their antibacterial, antifungal and antitubercular activities. Hybrids 5d, 5i, 5j and 5k exhibited equivalent antibacterial activity (MIC of 1.56 μg/mL) compared with standard drug ciprofloxacin against Staphylococcus aureus and Escherichia coli. Equal antifungal activity (MIC of 1.56 μg/mL) was shown by of hybrids 5j, 5k and 7d compared with standard Amphotericin-B. The inhibition of Mycobacterium tuberculosis at concentrations as low as 1.6 and 1.5 μg/mL by compounds 5f and 7d respectively indicates that these compounds can act as leads for development of newer anti-TB compounds. © 2012 Elsevier Ltd. All rights reserved.
Bhatt L.K.,Narsee Monjee Institute of Management and Higher Studies |
Addepalli V.,Narsee Monjee Institute of Management and Higher Studies
American Journal of Translational Research | Year: 2010
Interruptions of Matrix Metalloproteinase-2 (MMP-2) and Matrix Metalloproteinase-9 (MMP-9) have been shown to reduce the ensuing threatening risk factors of vascular complications of diabetes by alteration in Extracellular Matrix (ECM).We hypothesized that minocycline induced MMP-2 and MMP-9 inhibition can be enhanced by aspirin, a non-selective COX and tPA inhibitor and this combination can reduce progression of diabetic retinopathy. Diabetes was induced in male Wistar rats by streptozotocin (55 mg/kg i.p.). Four weeks after diabetes induction rats were treated with minocycline (50 mg/kg, p.o.) per se, aspirin (50 mg/kg, p.o.) per se, or minocycline in combination with aspirin for a period of four weeks. At the end of eighth week rats were anesthetized and electroretinograms were recorded. B-wave latency, B-wave amplitude and retinal permeability were measured. Histology was done and retinal thickness was measured. Zymography was carried out for MMP-2 and MMP-9 level determinations. B-wave amplitude was significantly decreased while B- wave latency was significantly increased in diabetic group when compared with normo-glycemic rats. Treatment with combination of minocycline and aspirin significantly reversed B-wave amplitude and latency compared with vehicle-treated diabetic controls. Blood retinal permeability and retinal thickness were also significantly attenuated by the treatment of minocycline in combination with aspirin. Results of the present study suggest that MMP-2 and MMP-9 inhibition in presence of COX inhibitor prevents the development of experimental diabetic retinopathy in rats and can be a potential approach for the treatment.
Tiwari R.N.,Narsee Monjee Institute of Management and Higher Studies |
Bonde C.G.,Narsee Monjee Institute of Management and Higher Studies
Journal of Pharmaceutical and Biomedical Analysis | Year: 2011
The objective of the present investigation was to separate, identify and characterize the major degradation products (DPs) of nelfinavir mesylate generated under hydrolytic, oxidative, photolytic and thermal stress conditions as advised in International Conference on Harmonization (ICH) guideline Q1A(R2). The drug was found to degrade under acidic, basic, oxidative and photolytic stress, while it was stable in neutral and thermal stress conditions. A total of three degradation products were formed, which were separated on a C-18 column employing a gradient HPLC method. A complete mass fragmentation pathway of the drug was first established with the help of multi-stage (MSn) and MS/TOF accurate mass studies. Then stressed samples were subjected to LC-MS/TOF studies, which provided their fragmentation pattern and accurate masses. The mass spectral data were employed to characterize the DPs and assign structures to them. The total information was also used to establish the degradation pathway of the drug. The degradation products were identified as 3-hydroxy-N-((2R,3R)-3-hydroxy-1-(phenylthio)butan-2-yl)-2-methylbenzamide and (3S,4aS,8aS)-N-tert-butyl-2-((2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(phenylsulfinyl)butyl)decahydroisoquinoline-3-carboxamide. © 2011 Elsevier B.V.
Majumdar S.H.,Narsee Monjee Institute of Management and Higher Studies
International Journal of Pharma and Bio Sciences | Year: 2012
Semecarpus anacardium (SA) popularly known as marking nut has been used in folklore for the treatment of a wide range of diseases. Extracts (hydro-alcoholic and oil) of SA were evaluated for their anticancer activity against Ehrlich ascites carcinoma (EAC) in nude mice. Extracts and standard drug (cyclophosphamide) at a dose of 20 mg/kg body weight were administered orally and continued for 10 consecutive days. The anticancer activity of SA was examined by determining the tumor area, tumor volume and tumor histology in experimental animal models. Both these extracts showed remarkable results in controlling the tumor in EAC bearing nude mice compared to the standard drug cyclophosphamide. Thus, the present study revealed that SA showed anticancer activity in the tested animal models.
Garud M.S.,Narsee Monjee Institute of Management and Higher Studies |
Kulkarni Y.A.,Narsee Monjee Institute of Management and Higher Studies
Current Diabetes Reviews | Year: 2014
Nephropathy is one of the major complications of diabetes which further directs to end stage renal disease. Extensive work has been done to find out the mechanisms involved in pathogenesis of the DN. Now, many researchers have been convinced that almost all of the molecular mediators and intracellular signaling pathways involved in progression of diabetic nephropathy have involvement in transforming growth factor beta (TGF- β) at some stage. In DN, hyperglycemia causes increase in the expression of TGF- β genes, TGF- β proteins and their receptors. Increased glucose level mediates these effects through activation of polyol pathway, protein kinase C pathway, hexosamine pathway, increases advanced glycation end products (AGE) and increases oxidative stress. Hyperglycemia also activates the TGF- β via activation of glucose transporters (GLUT), angiotensine II and platelet derived growth factor (PDGF). Activated TGF-β further leads to glomerular basement membrane (GBM) thickening and glomerulosclerosis through activation of connective tissue growth factor (CDGF) and vascular endothelial growth factor (VEGF). We have discussed the progression of hyperglycemia to DN via TGF- β, whose schematic presentation may serve as an effective way to understand the mechanisms and to find out an effective way for the management of diabetic nephropathy. © 2014 Bentham Science Publishers.
Kharkar P.S.,Narsee Monjee Institute of Management and Higher Studies |
Warrier S.,Narsee Monjee Institute of Management and Higher Studies |
Gaud R.S.,Narsee Monjee Institute of Management and Higher Studies
Future Medicinal Chemistry | Year: 2014
Reverse or inverse docking is proving to be a powerful tool for drug repositioning and drug rescue. It involves docking a small-molecule drug/ligand in the potential binding cavities of a set of clinically relevant macromolecular targets. Detailed analyses of the binding characteristics lead to ranking of the targets according to the tightness of binding. This process can potentially identify novel molecular targets for the drug/ligand which may be relevant for its mechanism of action and/or side effect profile. Another potential application of reverse docking is during the lead discovery and optimization stages of the drug-discovery cycle. This review summarizes the state-of-the-art and future prospects of the reverse docking with particular emphasis on computational molecular design. © 2014 Future Science Ltd.